IGF1 and neuroblastoma: Pretreatment with BRAFi did not change the ability of 2 of 3 tested melanoma cell lines to induce IGF-1 expression in NB cells; one cell line lost this ability presumably due to modulation of FGF-2 activity (Supplementary Fig. 9).